A Study in Healthy Men to Test How Well Different Doses of BI 3802876 Are Tolerated
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 59
- Registration Number
- NCT06081530
- Locations
- 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
- First Posted Date
- 2023-10-11
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 5550
- Registration Number
- NCT06077864
- Locations
- 🇺🇸
AMR Mobile, Mobile, Alabama, United States
🇺🇸Mobile Heart Specialists, PC, Mobile, Alabama, United States
🇺🇸The Institute for Liver Health, LLC, Chandler, Arizona, United States
DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer
- Conditions
- Small Cell Lung Carcinoma (SCLC)
- Interventions
- First Posted Date
- 2023-10-11
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 60
- Registration Number
- NCT06077500
- Locations
- 🇺🇸
Orlando Health Cancer Institute, Orlando, Florida, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇧🇪Brussels - UNIV Saint-Luc, Bruxelles, Belgium
A Study in Healthy Men to Test How BI 1810631 is Taken up in the Body When Taken With or Without Food
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT06075277
- Locations
- 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany
A Study in Healthy People to Test Whether Iclepertin Has an Effect on Cardiac Safety
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2023-10-06
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 56
- Registration Number
- NCT06070597
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the Blood
- First Posted Date
- 2023-10-06
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 14
- Registration Number
- NCT06070610
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
- Conditions
- ObesityDiabetes Mellitus, Type 2
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 756
- Registration Number
- NCT06066528
- Locations
- 🇬🇧
Bradford on Avon Health Centre, Bradford on Avon, United Kingdom
🇬🇧Mounts Bay Medical Limited, Hayle, United Kingdom
🇨🇳Pingxiang People's Hospital, Pingxiang, China
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 727
- Registration Number
- NCT06066515
- Locations
- 🇺🇸
Solaris Clinical Research, Meridian, Idaho, United States
🇺🇸Evanston Premier Healthcare Research LLC, Skokie, Illinois, United States
🇺🇸Velocity Clinical Research-Valparaiso-68883, Valparaiso, Indiana, United States
A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 146
- Registration Number
- NCT06056024
- Locations
- 🇺🇸
Mayo Clinic-Arizona, Phoenix, Arizona, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 138
- Registration Number
- NCT06058793
- Locations
- 🇬🇧
The Christie, Manchester, United Kingdom
🇦🇷Instituto Medico Especializado Alexander Fleming, Ciudad Autonoma de Bs As, Argentina
🇧🇷Pronutrir, Fortaleza, Brazil